74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Emergent BioSolutions Inc
Open
SectorHealthcare
8.02 -0.62
Overview
Share price change
24h
Min
7.96
Max
8.15
Income | -106M -55M |
|---|---|
Sales | -82M 149M |
P/E Sector Avg | 8.677 57.833 |
EPS | -0.43 |
Profit margin | -36.718 |
Employees | 900 |
EBITDA | -89M 6.9M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +44.06% upside |
Next Earnings | 6 May 2026 |
|---|
Market Cap | -147M 437M |
|---|---|
Previous open | 8.64 |
Previous close | 8.02 |
News Sentiment
By Acuity
50%
50%
156 / 351 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Emergent BioSolutions Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Emergent BioSolutions Inc Forecast
Price Target
By TipRanks
44.06% upside
12 Months Forecast
Average 12 USD 44.06%
High 12 USD
Low 12 USD
Based on 1 Wall Street analysts offering 12 month price targets forEmergent BioSolutions Inc - Dist in the last 3 months.
Sentiment
By Acuity
156 / 351 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Emergent BioSolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Live chat